RxDoctor Payments Data

Astrid de la Garza

Physician Assistant · McAllen, TXNPI 1689300964

Payments from drug & device makers

$8,233in general payments, 2019–2025

Across 228 payments — averaging $36.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Novo Nordisk$1K
  • Dexcom, Inc.$707
  • Amgen$653
  • Insulet Corporation$520
  • Corcept Therapeutics$476
  • plus $3K from 19 others

What the payments were for

  • Travel & lodging$1,23615%
  • Food & beverage$6,95484%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,233 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide451$594,529
MounjaroTirzepatide171$239,811
JardianceEmpagliflozin193$237,935
KerendiaFinerenone188$148,308
Synjardy XrEmpagliflozin/Metformin Hcl110$127,760
TrulicityDulaglutide77$121,601
Tresiba Flextouch U-100Insulin Degludec202$98,257
RybelsusSemaglutide54$76,588
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog68$52,932
Humulin R U-500 KwikpenInsulin Regular, Human30$44,191
VascepaIcosapent Ethyl59$43,391
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog67$40,944
Tresiba Flextouch U-200Insulin Degludec51$38,908
Fiasp FlextouchInsulin Aspart (Niacinamide)49$26,574
Lyumjev Kwikpen U-100Insulin Lispro-Aabc36$18,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,199$671,117505 claims
Lilly USA, LLCMounjaro, Trulicity, Baqsimi$411$370,298263 claims
Boehringer IngelheimJardiance, Synjardy Xr$401$365,695303 claims
BayerKerendia$382$148,308188 claims
AstraZenecaFarxiga$30$14,40015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →